Publication number: 20230399402
Abstract: The present invention includes engineered T cell receptor (TCR) proteins, nucleic acids, vectors, host cells, methods of treating cancer, and chimeric antigen receptor expressing T cell (CAR-T) comprising an alpha chain CDR3 having the amino acid sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 and/or a beta chain CDR3 having the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24, wherein the TCR is specific for a KRAS G12>V mutation peptide, antigen-MHC binding portions, and full length portions of the same.
Type:
Application
Filed:
November 3, 2021
Publication date:
December 14, 2023
Inventors:
Stephen P. Schoenberger, Bjoern Peters, Pandurangan Vijayanand, Zeynep Kosalglu-Yalcin, Aaron Miller, Ezra Cohen